Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of DS-3201b to evaluate the pharmacokinetics and safety after single oral administration, the relative bioavailability after administration of tablet and capsule formulations, and the effect of food on the pharmacokinetics in healthy Japanese subjects

Trial Profile

Phase 1 study of DS-3201b to evaluate the pharmacokinetics and safety after single oral administration, the relative bioavailability after administration of tablet and capsule formulations, and the effect of food on the pharmacokinetics in healthy Japanese subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs DS 3201 (Primary)
  • Indications Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 25 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 20 Apr 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 14 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top